首页> 中文期刊>国际医药卫生导报 >23价肺炎球菌疫苗联合流感疫苗对COPD急性发作的临床干预

23价肺炎球菌疫苗联合流感疫苗对COPD急性发作的临床干预

摘要

Objective To study the influence of 23-valent pneumococcus vaccine combined with influenza vaccine on COPD acute outbreak.Methods 69 cases of COPD in local community were randomly divided into vaccine group (36 cases) and control group (33 cases).Patients in vaccine group were vaccinated with 23-valent pneumococcus vaccine and influenza vaccine,adverse reactions were monitored for 2 weeks.All patients were followed for 1 year.days,Times,period and interval time of outbreak,hospital stay times,length of stay,severity of patients' condition and survival rate were analyzed.Results Times and severe level of outbreak significantly reduced in vaccine group (P < 0.05).Local adverse reactions were found in vaccine group,which remitted in 8-24 hours after symptomatic treatment.Conclusion 23-valent pneumococcus vaccine combined with influenza vaccine has a significant influence on COPD acute outbreak,with tolerated adverse reactions,worthy of clinical promotion.%目的 观察23价肺炎球菌疫苗与流感疫苗联合使用对COPD急性发作的临床疗效.方法 将本社区COPD患者69例,随机分为疫苗组(36例)与对照组(33例).对疫苗组所有接种对象疫苗接种后进行随访2周,监测不良反应,同时对研究对象进行跟踪随访1年,并从COPD急性发作的次数、天数、发作间距、住院次数、平均住院天数、病情严重程度、死亡率等方面进行对比.结果 疫苗组COPD急性发作的次数和程度较对照组明显较少,差异有统计学意义(P<0.05).疫苗组偶有局部不良反应,对症治疗后8~24小时均能自行缓解.结论 联合接种23价肺炎球菌疫苗与流感疫苗对COPD急性发作具有明显的干预效果,不良反应可以耐受,值得临床推广.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号